Evaxion Licenses Vaccine Candidate EVX-B3 to MSD
Evaxion, a cutting-edge TechBio company known for its innovative AI-Immunology™ technology, has made significant strides in advancing its vaccine development pipeline by out-licensing its candidate, EVX-B3, to MSD, the organization better known as Merck & Co., Inc. This strategic move comes after a successful collaboration, enabling Evaxion to receive a cash injection of $7.5 million.
Financial Implications and Future Prospects
This deal marks a substantial extension of Evaxion's financial runway, projecting it to sustain operations through the first half of 2027. MSD is set to take on all responsibilities for further development of EVX-B3. Moreover, Evaxion will remain eligible for up to $592 million in future development, regulatory, and sales milestone payments, along with royalties on sales, depending on the success of the vaccine.
About EVX-B3 and Its Significance
The candidate EVX-B3 is currently in its preclinical stages and addresses pressing global health issues associated with a specific pathogen that leads to recurrent infections and serious complications. The technology behind this vaccine was uncovered through Evaxion’s unique AI-Immunology™ platform, which identifies novel therapeutic targets that traditional methods might overlook.
Leadership Commentary on the Deal
Birgitte Rønø, the CSO and interim CEO of Evaxion, expressed excitement over the partnership with MSD, emphasizing the validation of their AI-Immunology™ platform. She highlighted their belief in MSD as a premier partner for maximizing the potential of this advanced vaccine candidate, reinforcing their strategy of forming high-impact partnerships.
Expansion of Collaboration for EVX-B2
In addition to EVX-B3, the collaboration encompasses another vaccine candidate, EVX-B2, aimed at addressing Gonorrhea. The evaluation period for EVX-B2 has been extended, allowing for further experiments which could potentially lead to its licensing decision by MSD in the first half of 2026. Should this option be exercised, Evaxion would also benefit from a $2.5 million payment, alongside similar development and sales milestone opportunities.
Investing In Future Technologies
Evaxion's management is focused on utilizing the new cash resources to enhance their AI-Immunology™ platform and fuel research and development initiatives aimed at high unmet medical needs. This strategic investment exemplifies their commitment to leveraging partnerships that enhance their capabilities and product offerings.
Details on Upcoming Communication Events
In light of these advancements, Evaxion will be conducting a conference call and webcast to discuss these developments in detail. The event is scheduled to take place at 2.30pm CT/8.30am ET, providing an opportunity for stakeholders to engage directly with the executive team and gain insight into these promising advancements.
Company Contact Information
For further inquiries, Evaxion A/S can be contacted through Mads Kronborg, Vice President of Investor Relations and Communication. He can be reached at +45 53 54 82 96 or via email at mak@evaxion.ai.
About Evaxion
Evaxion stands at the forefront of the biopharmaceutical industry, utilizing its AI-Immunology™ platform to revolutionize vaccine development. Their application of artificial intelligence in decoding the human immune system allows for novel approaches towards immunotherapy in various diseases, including cancer and infectious ailments. Their commitment to improving patient outcomes through innovative treatment options drives their operations to address significant global health challenges.
Frequently Asked Questions
What is the significance of Evaxion's partnership with MSD?
The partnership allows Evaxion to secure funding and strategic developmental support for its EVX-B3 vaccine, enhancing its operational future.
What are the financial benefits for Evaxion from this licensing deal?
Evaxion will receive $7.5 million upfront and may earn up to $592 million in milestone payments, plus sales royalties.
What does EVX-B3 target?
EVX-B3 is designed to combat a serious pathogen causing recurrent infections, aiming to fill a notable void in available vaccines.
When will Evaxion announce further developments on EVX-B2?
Decisions regarding EVX-B2's potential licensing are expected in the first half of 2026, following an extended evaluation phase.
How does Evaxion's AI-Immunology™ platform work?
This platform employs advanced AI algorithms to identify unique therapeutic targets for vaccine development, significantly enhancing research efficiency and efficacy.
